Eurofins Viracor, a leading specialty diagnostics laboratory, is proud to announce a groundbreaking advancement in respiratory infection diagnostics with the launch of a new bronchoalveolar lavage (BAL) specimen type for its NeXGen^® Fungal / Acid Fast Bacteria Next Generation Sequencing (NGS) assay.

Traditional methods for diagnosing these infections, such as cultures, are often time-consuming and may miss atypical or slow-growing species. The NeXGen^® Fungal / AFB NGS assay overcomes these limitations by utilizing the power of Next Generation Sequencing to analyze DNA, enabling precise identification of over 600 fungal and AFB species directly from BAL samples.

Key benefits of the NeXGen^® Fungal / AFB NGS assay with BAL specimens include:

• Identification of a wide range of fungal and AFB pathogens, including rare or atypical species.
• Significantly faster turnaround time compared to traditional cultures for these slow growing and difficult to identify pathogens.
• Potential for earlier initiation of appropriate therapy, reducing morbidity and mortality.

Eurofins Viracor's commitment to innovation in infectious disease diagnostics is exemplified by this advancement.